Skip to main content Accessibility help
×
Home

Antimalarial drug discovery – the path towards eradication

  • JEREMY N BURROWS (a1), EMILIE BURLOT (a1), BRICE CAMPO (a1), STEPHANIE CHERBUIN (a1), SARAH JEANNERET (a1), DIDIER LEROY (a1), THOMAS SPANGENBERG (a1), DAVID WATERSON (a1), TIMOTHY NC WELLS (a1) and PAUL WILLIS (a1)...

Summary

Malaria is a disease that still affects a significant proportion of the global human population. Whilst advances have been made in lowering the numbers of cases and deaths, it is clear that a strategy based solely on disease control year on year, without reducing transmission and ultimately eradicating the parasite, is unsustainable. This article highlights the current mainstay treatments alongside a selection of emerging new clinical molecules from the portfolio of Medicines for Malaria Venture (MMV) and our partners. In each case, the key highlights from each research phase are described to demonstrate how these new potential medicines were discovered. Given the increased focus of the community on eradicating the disease, the strategy for next generation combination medicines that will provide such potential is explained.

  • View HTML
    • Send article to Kindle

      To send this article to your Kindle, first ensure no-reply@cambridge.org is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about sending to your Kindle. Find out more about sending to your Kindle.

      Note you can select to send to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be sent to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

      Find out more about the Kindle Personal Document Service.

      Antimalarial drug discovery – the path towards eradication
      Available formats
      ×

      Send article to Dropbox

      To send this article to your Dropbox account, please select one or more formats and confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your <service> account. Find out more about sending content to Dropbox.

      Antimalarial drug discovery – the path towards eradication
      Available formats
      ×

      Send article to Google Drive

      To send this article to your Google Drive account, please select one or more formats and confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your <service> account. Find out more about sending content to Google Drive.

      Antimalarial drug discovery – the path towards eradication
      Available formats
      ×

Copyright

The online version of this article is published within an Open Access environment subject to the conditions of the Creative Commons Attribution licence .

Corresponding author

*Corresponding author. Medicines for Malaria Venture, ICC, 20 Route de Pré-Bois – PO Box 1826, 1215 Geneva 15, Switzerland. Tel: +41 22 799 45 70. Fax: +41 22 799 40 61. E-mail: burrowsj@mmv.org

References

Hide All
Alonso, P. L., Brown, G., Arevalo-Herrera, M., Binka, F., Chitnis, C., Collins, F., Doumbo, O. K., Greenwood, B., Hall, B. F., Levine, M. M., Mendis, K., Newman, R. D., Plowe, C. V., Rodriguez, M. H., Sinden, R., Slutsker, L. and Tanner, M. (2011). A research agenda to underpin malaria eradication. PLoS Medicine 8, e1000406.
Angulo-Barturen, I., Jimenez-Diaz, M. B., Mulet, T., Rullas, J., Herreros, E., Ferrer, S., Jimenez, E., Mendoza, A., Regadera, J., Rosenthal, P. J., Bathurst, I., Pompliano, D. L., Gomez de lasHeras, F. and Gargallo-Viola, D. (2008). A murine model of falciparum-malaria by in vivo selection of competent strains in non-myelodepleted mice engrafted with human erythrocytes. PLoS ONE 3, e2252.
Anthony, M. P., Burrows, J. N., Duparc, S., Moehrle, J. and Wells, T. N. C. (2012). The global pipeline of new medicines for the control and elimination of malaria. Malaria Journal 11, 316.
Baird, J. K. and Rieckmann, K. H. (2003). Can primaquine therapy for vivax malaria be improved? Trends in Parasitology 19, 115120.
Bousema, T., Okell, L., Shekalaghe, S., Griffin, J. T., Omar, S., Sawa, P., Sutherland, C., Sauerwein, R., Ghani, A. C. and Drakeley, C. (2010). Revisiting the circulation time of Plasmodium falciparum gametocytes: molecular detection methods to estimate the duration of gametocyte carriage and the effect of gametocytocidal drugs. Malaria Journal 9, 136.
Burrows, J. N., Chibale, K. and Wells, T. N. C. (2011 b). The state of the art in anti-malarial drug discovery and development. Current Topics in Medicinal Chemistry 11, 12261254.
Burrows, J. N., Hooft, R., Möhrle, J., Oeuvray, C. and Wells, T. N. C. (2013). Designing the next generation of medicines for malaria control and eradication. Malaria Journal in press.
Burrows, J. N., Leroy, D., Lotharius, J. and Waterson, D. (2011 a). Challenges in antimalarial drug discovery. Future Medicinal Chemistry 3, 1401.
Burrows, J. N. and Waterson, D. (2011). Discovering new medicines to control and eradicate malaria. Topics in Medicinal Chemistry 7, 125180.
Charman, S. A., Arbe-Barnes, S., Bathurst, I. C., Brun, R., Campbell, M., Charman, W. N., Chiu, F. C., Chollet, J., Craft, J. C., Creek, D. J., Dong, Y., Matile, H., Maurer, M., Morizzi, J., Nguyen, T., Papastogiannidis, P., Scheurer, C., Shackleford, D. M., Sriraghavan, K., Stingelin, L., Tang, Y., Urwyler, H., Wang, X., White, K. L., Wittlin, S., Zhou, L. and Vennerstrom, J. L. (2011). Synthetic ozonide drug candidate OZ439 offers new hope for a single-dose cure of uncomplicated malaria. Proceedings of the National Academy of Science, USA 108, 44004405.
Chico, R. M., Pittrof, R., Greenwood, B. and Chandramohan, D. (2008). Azithromycin-chloroquine and the intermittent preventive treatment of malaria in pregnancy. Malaria Journal 7, 255.
Coteron, J. M., Marco, M., Esquivias, J., Deng, X., White, K. L., White, J., Koltun, M., El Mazouni, F., Kokkonda, S., Katneni, K., Bhamidipati, R., Shackleford, D. M., Angulo Barturen, I., Ferrer, S. B., Jiménez-Díaz, M. B., Gamo, F. J., Goldsmith, E. J., Charman, W. N., Bathurst, I., Floyd, D., Matthews, D., Burrows, J. N., Rathod, P. K., Charman, S. A. and Phillips, M. A. (2011). Structure-guided lead optimization of triazolopyrimidine-ring substituents identifies potent Plasmodium falciparum dihydroorotate dehydrogenase inhibitors with clinical candidatepotential. Journal of Medicinal Chemistry 54, 55405561.
Dahl, E. L. and Rosenthal, P. J. (2007). Multiple antibiotics exert delayed effects against the Plasmodium falciparum apicoplast. Antimicrobial Agents and Chemotherapy 51, 34853490.
Delves, M., Plouffe, D., Scheurer, C., Meister, S., Wittlin, S., Winzeler, E. A., Sinden, R. E. and Leroy, D. (2012). The activities of current antimalarial drugs on the life cycle stages of Plasmodium: a comparative study with human and rodent parasites. PLoS Medicine 9, e1001169.
Dembele, L., Gego, A., Zeeman, A. M., Franetich, J. F., Silvie, O., Rametti, A., Le, G. R., Dereuddre-Bosquet, N., Sauerwein, R., van Gemert, G. J., Vaillant, J. C., Thomas, A. W., Snounou, G., Kocken, C. H. and Mazier, D. (2011). Towards an in vitro model of Plasmodium hypnozoites suitable for drug discovery. PLoS ONE 6, e18162.
Ding, X. C., Ubben, D. and Wells, T. N. (2012). A framework for assessing the risk of resistance for anti-malarials in development. Malaria Journal 11, 292.
Duffy, S. and Avery, V. M. (2012). Development and optimisation of a novel 384-well anti-malarial imaging assay validated for high-throughput screening. American Journal of Tropical Medicine and Hygiene 86, 8492.
Duparc, S., Lanza, C., Ubben, D., Borghini-Fuhrer, I. and Kellam, L. (2012). Optimal dose finding for novel antimalarial combination therapy. Tropical Medicine and International Health 17, 409413.
Gamo, F. J., Sanz, L. M., Vidal, J., de Cozar, C., Alvarez, E., Lavandera, J. L., Vanderwall, D. E., Green, D. V., Kumar, V., Hasan, S., Brown, J. R., Peishoff, C. E., Cardon, L. R. and Garcia-Bustos, J. F. (2010). Thousands of chemical starting points for antimalarial lead identification. Nature 465, 305310.
Guiguemde, W. A., Shelat, A. A., Bouck, D., Duffy, S., Crowther, G. J., Davis, P. H., Smithson, D. C., Connelly, M., Clark, J., Zhu, F., Jimenez-Diaz, M. B., Martinez, M. S., Wilson, E. B., Tripathi, A. K., Gut, J., Sharlow, E. R., Bathurst, I., El Mazouni, F., Fowble, J. W., Forquer, I., McGinley, P. L., Castro, S., Angulo-Barturen, I., Ferrer, S., Rosenthal, P. J., Derisi, J. L., Sullivan, D. J., Lazo, J. S., Roos, D. S., Riscoe, M. K., Phillips, M. A., Rathod, P. K., Van Voorhis, W. C., Avery, V. M. and Guy, R. K. (2010). Chemical genetics of Plasmodium falciparum. Nature 465, 311315.
Guiguemde, W. A., Shelat, A. A., Garcia-Bustos, J. F., Diagana, T., Gamo, F. J. and Guy, R. K. (2012). Global phenotypic screening for antimalarials. Chemistry and Biology 19, 116129.
Gujjar, R., Marwaha, A., El Mazouni, F., White, J., White, K. L., Creason, S., Shackleford, D. M., Baldwin, J., Charman, W. N., Buckner, F. S., Charman, S., Rathod, P. K. and Phillips, M. A. (2009). Identification of a metabolically stable triazolopyrimidine-based dihydroorotate dehydrogenase inhibitor with antimalarial activity in mice. Journal of Medicinal Chemistry 52, 18641872.
Jimenez-Diaz, M. B., Mulet, T., Viera, S., Gomez, V., Garuti, H., Ibanez, J., Alvarez-Doval, A., Shultz, L. D., Martinez, A., Gargallo-Viola, D. and Angulo-Barturen, I. (2009). Improved murine model of malaria using Plasmodium falciparum competent strains and non-myelodepleted NOD-scid IL2Rgammanull mice engrafted with human erythrocytes. Antimicrobial Agents and Chemotherapy 53, 45334536.
Meister, S., Plouffe, D. M., Kuhen, K. L., Bonamy, G. M., Wu, T., Barnes, S. W., Bopp, s. e., Borboa, R., Bright, A. T., Che, J., Cohen, S., Dharia, N. V., Gagaring, K., Gettayacamin, M., Gordon, P., Groessl, T., Kato, N., Lee, M. C., McNamara, C. W., Fidock, D. A., Nagle, A., Nam, T. G., Richmond, W., Roland, J., Rottmann, M., Zhou, B., Froissard, P., Glynne, R. J., Mazier, D., Sattabongkot, J., Schultz, P. G., Tuntland, T., Walker, J. R., Zhou, Y., Chatterjee, A., Diagana, T. T. and Winzeler, E. A. (2011). Imaging of Plasmodium liver stages to drive next-generation antimalarial drug discovery. Science 334, 13721377.
Möhrle, J., Duparc, S., Siethoff, C., van Giersbergen, P. L. M., Craft, J. C., Arbe-Barnes, S., Charman, S. A., Gutierrez, M., Wittlin, S. and Vennerstrom, J. L. (2012). First-in-man safety and pharmacokinetics of synthetic ozonide OZ439 demonstrates an improved exposure profile relative to other peroxide antimalarials. British Journal of Clinical Pharmacology 75, 524537.
Nagle, A., Wu, T., Kuhen, K., Gagaring, K., Borboa, R., Francek, C., Chen, Z., Plouffe, D., Lin, X., Caldwell, C., Ek, J., Skolnik, S., Liu, F., Wang, J., Chang, J., Li, C., Liu, B., Hollenbeck, T., Tuntland, T., Isbell, J., Chuan, T., Alper, P. B., Fischli, C., Brun, R., Lakshminarayana, S. B., Rottmann, M., Diagana, T., Winzeler, E. A., Glynne, R., Tully, D. C. and Chatterjeee, A. K. (2012). Imidazolopiperazines: lead optimization of the second-generation antimalarial agents. Journal of Medicinal Chemistry 55, 42444273.
Noedl, H., Se, Y., Schaecher, K., Smith, B. L., Socheat, D. and Fukuda, M. M. (2008). Evidence of artemisinin-resistant malaria in western Cambodia. New England Journal of Medicine 359, 26192620.
Payne, D. J., Gwynn, M. N., Holmes, D. J. and Pompliano, D. L. (2007). Drugs for bad bugs: confronting the challenges of antibacterial discovery. Nature Reviews Drug Discovery 6, 2940.
Phyo, A. P., Nkhoma, S., Stepniewska, K., Ashley, E. A., Nair, S., McGready, R., Ler, M. C., Al-Saai, S., Dondorp, A. M., Lwin, K. M., Singhasivanon, P., Day, N. P., White, N. J., Anderson, T. J. and Nosten, F. (2012). Emergence of artemisinin-resistant malaria on the western border of Thailand: a longitudinal study. Lancet 379, 19601966.
Plouffe, D., Brinker, A., McNamara, C., Henson, K., Kato, N., Kuhen, K., Nagle, A., Adrian, F., Matzen, J. T., Anderson, P., Nam, T.-g., Gray, N. S., Chatterjee, A., Janes, J., Yan, S. F., Trager, R., Caldwell, J. S., Schultz, P. G., Zhou, Y. and Winzeler, E. A. (2008). In silico activity profiling reveals the mechanism of action of antimalarials discovered in a high-throughput screen. Proceedings of the National Academy of Sciences, USA 105, 90599064.
Price, R. N., Tjitra, E., Guerra, C. A., Yeung, S., White, N. J. and Anstey, N. M. (2007). Vivax malaria: neglected and not benign. American Journal of Tropical Medicine and Hygiene 77(6 Suppl), 7987.
Rieckmann, K. H., McNamara, J. V., Frischer, H., Stockert, T. A., Carson, P. E. and Powell, R. D. (1968). Gametocytocidal and sporontocidal effectsof primaquine and of sulfadiazine with pyrimethamine in a chloroquine-resistant strain of Plasmodium falciparum. Bulletin of the World Health Organisation 38, 625632.
Roll Back Malaria: RBM Annual Report 2011 (2012). http://www.rollbackmalaria.org/
Rottmann, M., McNamara, C., Yeung, B. K., Lee, M. C., Zou, B., Russell, B., Seitz, P., Plouffe, D. M., Dharia, N. V., Tan, J., Cohen, S. B., Spencer, K. R., Gonzalez-Paez, G. E., Lakshminarayana, S. B., Goh, A., Suwanarusk, R., Jegla, T., Schmitt, E. K., Beck, H. P., Brun, R., Nosten, F., Renia, L., Dartois, V., Keller, T. H., Fidock, D. A., Winzeler, E. A. and Diagana, T. (2010). Spiroindolones, a potent compound class for the treatment of malaria. Science 329, 11751180.
Sanchez, B. A., Mota, M. M., Sultan, A. A. and Carvalho, L. H. (2004). Plasmodium berghei parasite transformed with green fluorescent protein for screening blood schizontocidal agents. International Journal for Parasitology 34, 485490.
Sanz, L. M., Crespo, B., De-Cozar, C., Ding, X. C., Llergo, J. L., Burrows, J. N., Garcia-Bustos, J. F. and Gamo, F. J. (2012). P. falciparum in vitro killing rates allow to discriminate between different antimalarial mode-of-action. PLOS ONE 7, e30949.
Sanz, L. M., Jimenez-Díaz, M. B., Crespo, B., De-Cozar, C., Almela, M. J., Angulo-Barturen, I., Castaneda, P., Ibanez, J., Fernandez, E. P., Ferrer, S., Herreros, E., Lozano, S., Martínez, M. S., Rueda, L., Burrows, J. N., García-Bustos, J. F. and Gamo, F. J. (2011). Cyclopropylcarboxamides, a chemically novel class of antimalarial agents identified in a phenotypic screen. Antimicrobial Agents and Chemotherapy 55, 57405745.
Sinden, R. E. (2009). Malaria, sexual development and transmission: retrospect and prospect. Parasitology 136, 14271434.
Sinden, R. E., Carter, R., Drakeley, C. and Leroy, D. (2012 a). The biology of sexual development of Plasmodium: the design and implementation of transmission-blocking strategies. Malaria Journal 11, 70.
Sinden, R. E., Delves, M. J. and Blagborough, A. M. (2012 b). Targeting the parasite in the mosquito: rationale and practicality. Malaria Journal 11(Suppl 1), O5.
Spangenberg, T., Burrows, J. N., Kowalczyk, P., McDonald, S., Wells, T. N. C. and Willis, P. (2013). The open access malaria box: a drug discovery catalyst for neglected diseases. PLoS ONE, in press.
The malERA Consultative Group on Drugs. (2011). A research agenda for malaria eradication: drugs. PLoS Medicine 8, e1000402.
Vennerstrom, J. L., Arbe-Barnes, S., Brun, R., Charman, S. A., Chiu, F. C. K., Chollet, J., Dong, Y., Dorn, A., Hunziker, D., Matile, H., McIntosh, K., Padmanilayam, M., Santo, T. J., Scheurer, C., Scorneaux, B., Tang, Y., Urwyler, H., Wittlin, S. and Charman, W. N. (2004). Identification of an antimalarial synthetic trioxolane drug development candidate. Nature 430, 900904.
Wells, T. N. C., Burrows, J. N. and Baird, J. K. (2010). Targeting the hypnozoite reservoir of Plasmodium vivax: the hidden obstacle to malaria elimination. Trends in Parasitology 26, 145151.
White, M. T., Conteh, L., Cibulskis, R. and Ghani, A. C. (2011). Costs and cost-effectiveness of malaria control interventions – a systematic review. Malaria Journal 10, 337.
WHO (2010). Guidelines for the Treatment of Malaria, 2nd Edn. Geneva, Switzerland. ISBN 978 92 4 154792.4
WHO (2011). WHO World Malaria Report 2011. Geneva, Switzerland.
WHO (2012 a). WHO Policy Recommendation: Seasonal Malaria Chemoprevention (SMC) for Plasmodium falciparum malaria control in highly seasonal transmission areas of the Sahel sub-region in Africa. Geneva, Switzerland.
WHO (2012 b). WHO Policy Recommendation: Single dose Primaquine as a gametocytocide in Plasmodium falciparum malaria. Geneva, Switzerland.
Yeung, B. K., Zou, B., Rottmann, M., Lakshminarayana, S. B., Ang, S. H., Leong, S. Y., Tan, J., Wong, J., Keller-Maerki, S., Fischli, C., Goh, A., Schmitt, E. K., Krastel, P., Francotte, E., Kuhen, K., Plouffe, D., Henson, K., Wagner, T., Winzeler, E. A., Petersen, F., Brun, R., Dartois, V., Diagana, T. and Keller, T. H. (2010). Spirotetrahydrobetacarbolines (spiroindolones): a new class of potent and orally efficacious compounds for the treatment of malaria. Journal of Medicinal Chemistry 53, 51555164.
Yuthavong, Y., Tarnchompoo, B., Vilaivan, T., Chitnumsub, P., Kamchonwongpaisan, S., Charman, S. A., McLennan, D. N., White, K. L., Vivas, L., Bongard, E., Thongphanchang, C., Taweechai, S., Vanichtanankul, J., Rattanajak, R., Arwon, U., Fantauzzi, P., Yuvaniyama, J., Charman, W. N. and Matthews, D. (2012). Malarial dihydrofolate reductase as a paradigm for drug development against a resistance-compromised target. Proceedings of the National Academy of Sciences, USA 109, 16823–1682.

Keywords

Metrics

Full text views

Total number of HTML views: 0
Total number of PDF views: 0 *
Loading metrics...

Abstract views

Total abstract views: 0 *
Loading metrics...

* Views captured on Cambridge Core between <date>. This data will be updated every 24 hours.

Usage data cannot currently be displayed